Question 1

Purpose of the Procedure

Accepted Answer

Determine if the cancer is HER2-positive. Identify eligibility for targeted therapies like Trastuzumab. Predict prognosis and tumor aggressiveness.

Question 2

Target Groups

Accepted Answer

Patients with newly diagnosed invasive breast cancer. Patients with advanced or metastatic gastric cancer. Recurrent cancer cases to re-evaluate receptor status.

Question 3

Understanding Results

Accepted Answer

Positive (3+): Indicates a high likelihood of responding to targeted therapy. Negative (0 or 1+): Indicates targeted therapy may not be effective. Equivocal (2+): Requires additional testing via FISH for confirmation.

Precision HER2 Testing for Cancer - HER2/neu Expression Analysis (IHC/FISH)